期刊文献+

丙酮酸激酶M2与CD276在头颈鳞癌中的表达及临床意义

Expression and significance of pyruvate kinase M2 and CD276 in head and neck squamous cell carcinoma
下载PDF
导出
摘要 目的:观察丙酮酸激酶M2(pyruvate kinase M2,PKM2)和B7H3(CD276)在头颈鳞癌(head and neck squamous cell carcinoma,HNSCC)和正常口腔黏膜中的表达,探讨PKM2与CD276的相关性。方法:应用免疫组织化学方法检测PKM2和CD276在70例HNSCC及18例正常口腔黏膜组织中的表达水平,分析PKM2和CD276的表达水平与HNSCC临床病理特征的关系。采用SPSS 13.0软件包对数据进行统计学分析。结果:PKM2和CD276在HNSCC的表达水平比正常黏膜组织高。PKM2和CD276的表达水平与TNM分期相关(P<0.05),与患者性别、年龄、病理分级无相关性(P>0.05)。CD276在头颈鳞癌中的表达与PKM2的表达呈正相关。结论:PKM2和CD276在HNSCC的高表达与肿瘤恶性进展相关。PKM2可能通过增加CD276的表达而参与免疫调控。 PURPOSE:To investigate the expression and correlation between pyruvate kinase M2(PKM2)and B7 H3(CD276)in head and neck squamous cell carcinoma(HNSCC)patients.METHODS:Immunohistochemical staining was used to detect the expression of PKM2 and CD276 in 70 HNSCC tissues and 18 normal oral mucosa tissues.The relationship between the expression of PKM2 and CD276 in OSCC tissues and clinical pathological characteristics were analyzed using SPSS13.0 software package.RESULTS:The expression of PKM2 and CD276 in HNSCC was significantly higher than that in normal oral mucosa.The expression of PKM2 and CD276 was strongly associated with TNM stage(P<0.05),while no correlation with gender,age,pathological differentiation grade(P>0.05).The expression of CD276 was positively correlated with the expression of PKM2 in HNSCC.CONCLUSIONS:High expression of PKM2 and CD276 in HNSCC was closely related with malignant progression,and PKM2 may participate in immune regulation by promoting CD276 expression.
作者 常涵月 马海龙 杨溪 张志愿 CHANG Han-yue;MA Hai-long;YANG Xi;ZHANG Zhi-yuan(Key Laboratory of Oral Medicine,Guangzhou Institute of Oral Disease,Stomatology Hospital of Guangzhou Medical University,Guangzhou 510140,Gungdong Province;Department of Oromaxillofacial Head and Neck Oncology,Shanghai Ninth People’s Hospital,College of Stomatology,Shanghai Jiao Tong University School of Medicine,National Clinical Research Center for Oral Disease,Shanghai Key Laboratory of Stomatology&Shanghai Reasearch Institute of Stomatology,Shanghai 200011,China)
出处 《中国口腔颌面外科杂志》 CAS 2020年第4期297-301,共5页 China Journal of Oral and Maxillofacial Surgery
基金 国家自然科学基金(81902747,81602367)。
关键词 丙酮酸激酶M2 CD276 头颈鳞癌 Pyruvate kinase M2 CD276 head and neck squamous cell carcinoma
  • 相关文献

参考文献1

二级参考文献32

  • 1Oremek GM, Sapoutzis N, Kramer W, Bickeboller R, Jonas D.Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.Anticancer Res 2000; 20:5095-5098.
  • 2Roigas J, Deger S, Schroeder J, Wille A, Turk I, Brux B, Jung K,Schnorr D, Loening SA. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res 2003; 26.
  • 3Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loenng SA. Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients. Urology A 2000; 39:554-556.
  • 4Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E. Comparison of the tumor markers tumor M2-PK, CEA,CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.Anticancer Res 2000; 20:5053-5058.
  • 5Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G,Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 2002; 22(1A): 311-318.
  • 6Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.Anticancer Res 2003: 23(2A): 899-906.
  • 7Schneider J, Peltri G, Bitterlich N, Philipp M, Velcovsky HG,Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. Clin Exp Med 2003;2:185-191.
  • 8Pottek T, Muller M, Blum T, Hartmann M. Tu-M2-PK in the blood of testicular and cubital veins in men with testicular cancer. Anticancer Res 2000; 20:5029-5033.
  • 9Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE,Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20:5077-5082.
  • 10Hoopmann M, Warm M, Mallmann P, Thomas A, Gohring UJ,Schondorf T. Tumor M2 pyruvate kinase-determination in breast cancer patients receiving trastuzumab therapy. Cancer Lett 2002; 187:223-228.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部